Previous studies have found the tumor-infiltrated CD8 positive T cells prior to immune checkpoint inhibitors could serve as an indicator for the response of anti-PD-1/L1 therapy (Tumeh et al., 2014; McDermott et al., 2018). This evidence concerns the gene CD8A and neoplasm.